Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript
Great. Good afternoon, everybody, and thank you for continuing on here. It's always a pleasure to moderate panels with the Prothena team, Gene and Tran. So thank you guys as always. Gene, do you want to just kick it off and give some opening remarks on the recent Prothena updates and as brief as you can, so we can get into Q&A? Is that cool?
You got it. Thanks, Paul. And thanks very much for having us. We always enjoy these discussions. So yeah, I mean, just very briefly for those that don't know Prothena well, we focus on diseases that are caused by dysregulation of protein, which takes us into two very important therapeutic areas of peripheral amyloid diseases. So these are diseases like AL amyloidosis, ATTR amyloidosis, and of course, central nervous system disorders here, diseases like Alzheimer's disease, Parkinson's disease and the like.
And so our portfolio is focused in those spaces. We have programs
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |